Translation of "Vasospasm" in German

Increased plasma concentrations of ergot derivatives leading to acute ergot toxicity, including vasospasm and ischaemia.

Vasospasm in the ulnar artery would explain the hand.

It prevents vasospasm and blood clots, improves blood circulation and dilutes blood.

These diseases include health issues such as arthritis, atherosclerosis, and vasospasm.

Vasospasm and the risk of suffering it are reduced with the passage of time.

The effect of the sclerosing agent has caused a vasospasm.

Accepted, provided that the deterioration is due to vasospasm.

When the "white" occurs vasospasm, leading to chills.

His laboratory investigates mechanisms and pathophysiology of cerebral vasospasm after subarachnoid hemorrhage.

The drug will help only if high blood pressure caused by vasospasm.

From the pathogenic point of view, it is likely that vasospasm is responsible for these events.

The vasospasm is provoked by atherosclerotic deposits, stress, or destructive habits of the patient.

Variant angina (Prinzmetala) caused by vasospasm due to physical triggers;

In this case, it is not uncommon manifestation of vasospasm, which is unacceptable.

Under the influence of cold, a vasospasm occurs, a decrease in the phenomena of ischemia.

Other drugs may also be given  to reduce the threat of vasospasm.

Increased plasma concentrations of ergot derivatives leading to acute ergot toxicity, including vasospasm and ischaemia (see section 4.5).

Potential for serious and/or life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.

The literature contains publications about an increased incidence of certain neurological deficits such as hydrocephaly, cerebral ischaemia or cerebral vasospasm associated to the use of antifibrinolytic agents in the treatment of subarachnoid haemorrhage (SAH).

Co-administration may result in competitive inhibition of the metabolism of these active substances thus increasing their plasma level and leading to serious and / or life-threatening adverse reactions such as cardiac arrhythmia (e.g. amiodarone, astemizole, bepridil, cisapride, pimozide, quinidine, terfenadine) or peripheral vasospasm or ischaemia (e.g. ergotamine, dihydroergotamine).

Co-administration may result in competitive inhibition of the metabolism of these medicinal products and create the potential for serious and/or life-threatening adverse events such as cardiac arrhythmia (e.g. amiodarone, bepridil, quinidine, terfenadine, astemizole, cisapride, pimozide), respiratory depression and /or prolonged sedation (e.g. oral triazolam and oral midazolam (for caution on parenterally administered midazolam, see section 4.5)) or peripheral vasospasm or ischaemia and ischaemia of other tissues, including cerebral or myocardial ischaemia (e.g. ergot derivatives).

Concomitant administration of Kaletra and ergot alkaloids are contraindicated as it may lead to acute ergot toxicity, including vasospasm and ischaemia (see section 4.3).

Co-administration of Genvoya and some medicinal products that are primarily metabolised by CYP3A may result in increased plasma concentrations of these products, which are associated with the potential for serious or life-threatening adverse reactions such as peripheral vasospasm or ischaemia (e.g., dihydroergotamine, ergotamine, ergometrine), or myopathy, including rhabdomyolysis (e.g., simvastatin, lovastatin), or prolonged or increased sedation or respiratory depression (e.g., orally administered midazolam or triazolam).

Cerebral vasospasm explains both.

Such drop formulations can also be easily administered by stomach tube, without complications, to unconscious patients suffering from a vasospasm following subarachnoidal haemorrhage.

The effect of this is an advantageous increase in the inhibition of platelet aggregation, and an increase in granulocyte activity, vasospasm and an increasing vasodilating activity as well as a potentiation of the effect of endothelium-derived relaxing factor.

In a further embodiment, the invention also relates to the use of the compounds of the formula I and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of ischaemia as a consequence of cardiac arrest, asystolia and delayed ventricular arrhythmia, heart operation, cardiopulmonary bypass operation, organ transplant, spinal cord trauma, head trauma, stroke, thromboembolic stroke, haemorrhagic stroke, cerebral vasospasm, hypotonia, hypoglycaemia, status epilepticus, an epileptic fit, anxiety, schizophrenia, a neurodegenerative disorder, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS) or neonatal stress.